Novartis shares fall as del-desiran flunks Phase 3 myotonic dystrophy trial
Novartis AG (ADR) (NYSE:NVS) shares fell as much as 10% after the company's del-desiran failed to meet the primary endpoint in its pivotal Phase 3 HARBOR...
Company
Sarepta Therapeutics Inc
NASDAQ:SRPT
Sarepta Therapeutics Inc., formerly AVI BioPharma, Inc., is a biopharmaceutical company focused on the discovery and development of ribonucleic acid (RNA)-based therapeutics for the treatment of both rare and infectious diseases.
45 stories · page 1 of 3
EARLY MOVERS: Wells Fargo in focus as it unveils jobs cull; while Pier 1 Imports shares take a dive
Also in the frame before the New York bell was United Natural Foods Inc and Sarepta Therapeutics Inc..
PRE-MARKET MOVERS: Boeing Co flying higher before the bell after FedEx deal; Sarepta Therapeutics also higher
Also in play in pre-market before the New York bell is AT&T Inc and Sarepta Therapeutics Inc
Small-Cap Snapshot: Biohaven Pharmaceuticals shares boosted by royalty funding deal
Solid Biosciences, Astrotech and Wave Life Sciences are also making news Tuesday
Sarepta Therapeutics jumps as Morgan Stanley ups its rating to ‘overweight’, targets US$60 a share
Morgan Stanley analyst Matthew Harrison said: "We expect continued topline beats to drive near-term upside as Sarepta's underappreciated pipeline drives long-term optionality”
Sarepta soars on positive results from early-stage DMD clinical trial
The phase I/II study of Golodirsen hit all of its primary and secondary endpoints, with patients seeing a significant rise in dystrophin which is vital for muscle function